12 
MINUTES OF MEETING - June 5-6 
was willing to include this suggestion in her motion. The RAC accepted 
Ms. King's motion by a vote of fourteen in favor, none opposed, and four 
abstentions. There was further discussion of this issue on June 6, 1980 
(see Section XXV of the Minutes). 
III. MINUTES OF MARCH 6-7, 1980 MEETING 
The RAC reviewed the minutes of the March 6-7, 1980 meeting (tab 902). 
Mr. Thornton said he had found three substantive errors and suggested 
several minor editorial changes. Dc. Walters suggested that the paragraph 
describing the Eli Lilly and Company facility be clarified. He also 
proposed a modification of the report of Dr. Burnett Barkley's statement. 
Dr. Walters read his modified language. Mr. Thornton concurred with 
Dr. Walters' suggestions and moved acceptance of the minutes with the 
suggested modifications. Dr. Young said he would suggest several minor 
corrections to ORDA. With these corrections, the minutes were approved 
unanimously with one member abstaining. 
IV. REPORT OF RISK ASSESSMENT MEETING 
Dr. Krause said that the National Institute of Allergy and Infectious 
Diseases (NIAID) , has let a contract to develop a comprehensive training 
course on microbiological principles and safety practices. This course 
will be developed in accord with the recommendations of the American 
Society for Microbiology (ASM) . He noted that the ASM suggested that 
training in all areas of microbiology was necessary and that recombinant 
DMA techniques are simply a subcategory of microbiological research. 
Dr. Krause also said that NIAID would convene a meeting of Institutional 
Biosafety Committee (IBC) chairmen on November 24 and 25, 1980. He 
invited all RAC members to attend this meeting. This will be the first 
stage in an evaluation of the functioning of IBCs. 
Dr. Krause then reported on the Risk Assessment Meeting held in Pasadena, 
California on April 5-6, 1980 (tab 896, 898, 898A) . He said that 92 
scientists with expertise in immunology, endocrinology, physiology, micro- 
biology and infectious diseases attended. He said that the Pasadena 
meeting addressed two issues: 
1. the potential direct adverse effects of hormone-producing or 
active polypeptide-producing strains of Escherichia coli K-12, 
and 
2. the potential production of antibodies or autoreactive cells 
by individuals colonized by Escherichia coli K-12 elaborating 
eukaryotic polypeptides. 
[ 112 ] 
